272 related articles for article (PubMed ID: 9021203)
1. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
Klepser ME; Marangos MN; Zhu Z; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 1997 Feb; 41(2):435-9. PubMed ID: 9021203
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid.
Van der Auwera P; Duchateau V; Lambert C; Husson M; Kinzig M; Sörgel F
Antimicrob Agents Chemother; 1993 Sep; 37(9):1860-8. PubMed ID: 8239597
[TBL] [Abstract][Full Text] [Related]
3. [Bactericidal activity of combinations of ticarcillin-clavulanic acid or other beta-lactams (amoxicillin, piperacillin-tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium].
Leclercq R; Duval J
Pathol Biol (Paris); 1995 Apr; 43(4):245-52. PubMed ID: 7567109
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).
Eliopoulos GM; Klimm K; Ferraro MJ; Jacoby GA; Moellering RC
Diagn Microbiol Infect Dis; 1989; 12(6):481-8. PubMed ID: 2560420
[TBL] [Abstract][Full Text] [Related]
6. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
Lister PD
Pharmacotherapy; 2000 Sep; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
[TBL] [Abstract][Full Text] [Related]
7. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of YTR 830.
Jacobs MR; Aronoff SC; Appelbaum PC; Yamabe S
J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
Gatermann S; Marre R
Infection; 1991; 19(2):106-9. PubMed ID: 1646771
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.
Fass RJ; Prior RB
Antimicrob Agents Chemother; 1989 Aug; 33(8):1268-74. PubMed ID: 2552904
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
Stratton CW; Weeks LS; Aldridge KE
Diagn Microbiol Infect Dis; 1992; 15(4):321-30. PubMed ID: 1611847
[TBL] [Abstract][Full Text] [Related]
13. Comparison of ampicillin-sulbactam and ticarcillin-clavulanic acid in patients with chronic renal failure: effects of differential pharmacokinetics on serum bactericidal activity.
Hardin TC; Butler SC; Ross S; Wakeford JH; Jorgensen JH
Pharmacotherapy; 1994; 14(2):147-52. PubMed ID: 8197032
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
Burgess DS; Waldrep T
Clin Ther; 2002 Jul; 24(7):1090-104. PubMed ID: 12182254
[TBL] [Abstract][Full Text] [Related]
15. Piperacillin tazobactam compared with co-amoxiclav, ampicillin plus sulbactam and timentin against beta-lactamase-producing clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca.
Traub WH; Leonhard B
Chemotherapy; 1995; 41(5):345-52. PubMed ID: 8521736
[TBL] [Abstract][Full Text] [Related]
16. Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results.
Jones RN; Sutton LD; Cantrell HF; Lankford RB
Diagn Microbiol Infect Dis; 1994 Nov; 20(3):143-9. PubMed ID: 7874881
[TBL] [Abstract][Full Text] [Related]
17. Activities and time-kill studies of selected penicillins, beta-lactamase inhibitor combinations, and glycopeptides against Enterococcus faecalis.
Hoellman DB; Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 Apr; 42(4):857-61. PubMed ID: 9559796
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of the in vitro activity of piperacillin/tazobactam.
Daley D; Mulgrave L; Munro R; Neville S; Smith H; Dimech W
Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.
Occhipinti DJ; Pendland SL; Schoonover LL; Rypins EB; Danziger LH; Rodvold KA
Antimicrob Agents Chemother; 1997 Nov; 41(11):2511-7. PubMed ID: 9371358
[TBL] [Abstract][Full Text] [Related]
20. Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Dec; 38(12):2905-7. PubMed ID: 7695281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
